SE9901428D0 - Amphibodies - Google Patents
AmphibodiesInfo
- Publication number
- SE9901428D0 SE9901428D0 SE9901428A SE9901428A SE9901428D0 SE 9901428 D0 SE9901428 D0 SE 9901428D0 SE 9901428 A SE9901428 A SE 9901428A SE 9901428 A SE9901428 A SE 9901428A SE 9901428 D0 SE9901428 D0 SE 9901428D0
- Authority
- SE
- Sweden
- Prior art keywords
- amphibody
- cell growth
- nerve cell
- present
- comprised
- Prior art date
Links
- 230000005709 nerve cell growth Effects 0.000 abstract 3
- 230000002349 favourable effect Effects 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002858 neurotransmitter agent Substances 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9901428A SE9901428D0 (sv) | 1999-04-21 | 1999-04-21 | Amphibodies |
AU46343/00A AU4634300A (en) | 1999-04-21 | 2000-04-20 | Nerve cell growth modulators (amphibodies) |
EP00928054A EP1210120A1 (en) | 1999-04-21 | 2000-04-20 | Nerve cell growth modulators (amphibodies) |
PCT/SE2000/000764 WO2000064482A1 (en) | 1999-04-21 | 2000-04-20 | Nerve cell growth modulators (amphibodies) |
US11/710,541 US20080241157A1 (en) | 1999-04-21 | 2007-02-26 | Nerve cell growth modulators (amphibodies) |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9901428A SE9901428D0 (sv) | 1999-04-21 | 1999-04-21 | Amphibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
SE9901428D0 true SE9901428D0 (sv) | 1999-04-21 |
Family
ID=20415301
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE9901428A SE9901428D0 (sv) | 1999-04-21 | 1999-04-21 | Amphibodies |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080241157A1 (sv) |
EP (1) | EP1210120A1 (sv) |
AU (1) | AU4634300A (sv) |
SE (1) | SE9901428D0 (sv) |
WO (1) | WO2000064482A1 (sv) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE500842T1 (de) | 2002-05-04 | 2011-03-15 | Acorda Therapeutics Inc | Zusammensetzungen und verfahren zur förderung des neuronalen wachstums |
US20060153827A1 (en) * | 2002-08-15 | 2006-07-13 | Gruskin Elliott A | Chimeric protein |
US7959914B2 (en) | 2003-05-16 | 2011-06-14 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
MXPA05012306A (es) * | 2003-05-16 | 2006-04-18 | Acorda Therapeutics Inc | Proteinas de fusion para el tratamiento del snc. |
US8906363B2 (en) | 2003-05-16 | 2014-12-09 | Acorda Therapeutics, Inc. | Fusion proteins for the treatment of CNS |
JP4926962B2 (ja) | 2004-05-18 | 2012-05-09 | アコーダ セラピューティクス、インク. | コンドロイチン分解酵素とその安定な製剤の精製法 |
CA2623635C (en) | 2005-09-26 | 2013-04-02 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase abci mutants |
EP2079835B1 (en) | 2006-10-10 | 2014-03-26 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase abci mutants |
CN105829542A (zh) * | 2013-12-20 | 2016-08-03 | 豪夫迈·罗氏有限公司 | 改进的重组多肽生产方法 |
WO2015091130A1 (en) * | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | Method for improving the recombinant production of soluble fusion polypeptides |
MY193078A (en) | 2015-06-24 | 2022-09-26 | Hoffmann La Roche | Anti-transferrin receptor antibodies with tailored affinity |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
IL312251A (en) | 2015-10-02 | 2024-06-01 | Hoffmann La Roche | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1341050C (en) * | 1988-11-04 | 2000-07-11 | Martin E. Schwab | Neurite growth regulatory factors |
US5672683A (en) * | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
WO1994017831A1 (en) * | 1993-02-11 | 1994-08-18 | Erziehungsdirektion Of The Canton Zurich | A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration |
ATE175677T1 (de) * | 1993-10-18 | 1999-01-15 | Regeneron Pharma | Heterodimere der wachstumsfaktoren |
CA2173731A1 (en) * | 1993-11-08 | 1995-05-18 | Martin Grumet | Neuron-glia cell adhesion molecule, ng-cam, in treatment of nerve damage |
JP4493854B2 (ja) * | 1998-12-23 | 2010-06-30 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | リガンドの生物学的活性を増強する方法 |
-
1999
- 1999-04-21 SE SE9901428A patent/SE9901428D0/sv unknown
-
2000
- 2000-04-20 AU AU46343/00A patent/AU4634300A/en not_active Abandoned
- 2000-04-20 EP EP00928054A patent/EP1210120A1/en not_active Ceased
- 2000-04-20 WO PCT/SE2000/000764 patent/WO2000064482A1/en active Application Filing
-
2007
- 2007-02-26 US US11/710,541 patent/US20080241157A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU4634300A (en) | 2000-11-10 |
US20080241157A1 (en) | 2008-10-02 |
WO2000064482A1 (en) | 2000-11-02 |
EP1210120A1 (en) | 2002-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE9901428D0 (sv) | Amphibodies | |
WO2001016114A3 (en) | Heterocyclic compounds and methods for modulating cxcr3 function | |
WO2002036743A3 (en) | Antisense modulation of calreticulin expression | |
EP1461352A4 (en) | ANTISENSE MODULATION OF CONJUNCTIVE TISSUE GROWTH FACTOR EXPRESSION | |
EP2256200A3 (en) | Modulation of eIF4E expression | |
WO2004007679A3 (en) | Dendritic cell pontentiation | |
WO2004075865A3 (en) | Selective modulation of tlr-mediated biological activity | |
MY124151A (en) | Epothilone derivatives | |
WO2003086280A3 (en) | Immunostimulatory g,u-containing oligoribonucleotides | |
WO2005042497A3 (en) | Benzimidazoles useful as modulators of ion channels | |
AU6589094A (en) | 7-deazapurine modified oligonucleotides | |
CA2394984A1 (en) | Novel plant expression constructs | |
TR199700610A3 (tr) | Düsük molekül agirlikli çözünür, tümör nekroz faktörü tip-I ve tip-II proteinleri. | |
PT1117672E (pt) | Modulação anti-sentido da expressão de survivina | |
ATE294152T1 (de) | Substituierte tetrahydro-naphtaline und analoge verbindungen | |
WO2003097662A8 (en) | Antisense modulation of apolipoprotein b expression | |
WO2004006667A3 (en) | Methods for the regeneration and transformation of cotton | |
WO2004048534A3 (en) | Modulation of cytokine-inducible kinase expression | |
WO2001014584A3 (en) | Methods of identifying anti-viral agents | |
WO2003022222A3 (en) | Antisense modulation of protein kinase r expression | |
WO2004071468A3 (en) | Short immunomodulatory oligonucleotides | |
WO2000018801A3 (en) | Ncam binding compounds | |
EP1212456A4 (en) | ANTISENSE MODULATION OF SHP-2 EXPRESSION | |
EP1250347A4 (en) | ANTISENSE MODULATION OF THE AKT-3 EXPRESSION | |
WO2000040232A3 (en) | Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions |